Versiti Collaborates with Velico on Blood Center Education Program
Versiti, Inc., a national leader in blood health solutions, is excited to join forces with Velico, a pioneer in spray dried plasma manufacturing technology, through the Blood Center Education Program (BCEP). This collaboration aims to achieve a common goal of improving patient outcomes by leveraging cutting-edge technology in blood health.
Understanding the Blood Center Education Program
The BCEP is designed to provide strategic partnerships for blood centers, offering them the opportunity to gain practical experience using Velico's FrontlineODP™ system for spray drying plasma. This program not only allows participants to assess the technology's operational viability but also encourages them to provide valuable feedback on its commissioning and effective usage.
The Importance of Spray Dried Plasma
In emergency medical situations, the availability of plasma is crucial. The FrontlineODP™ system represents an innovative solution for creating spray dried plasma quickly, thus enhancing its availability precisely when and where it is required the most. This technology revolutionizes plasma storage and distribution, providing advantages such as expedited rehydration, extended shelf life, simplified transportation, and minimized product wastage.
Leadership Insights on the Collaboration
"This partnership exemplifies our mutual commitment to saving lives through advancements in blood product technology," shares Richard Meehan, President, and CEO of Velico. Both organizations share a profound dedication to transforming blood health solutions through innovation.
Dr. Barbara Bryant, Executive Vice President and Chief Medical Officer at Versiti, adds, "Versiti has a long-standing tradition of innovation in the transfusion medicine community since 1947. Our commitment to enhancing blood-based technologies plays a pivotal role in our mission. The BCEP provides an exciting avenue to engage with new technologies that we believe will significantly benefit prehospital care providers in the future."
Funding and Development Initiatives
Velico's development initiatives are supported in part by federal funding through the Department of Health and Human Services’ Administration for Strategic Preparedness and Response. This partnership illustrates a robust commitment to advancing transfusion medicine in public health.
The FrontlineODP™ Dried Plasma System, while currently investigational, is undergoing clinical trials aimed at establishing its efficacy and approval for use both in the U.S. and internationally.
About Velico and Its Mission
Velico, Inc. is a forward-thinking medical technology company with its base in Beverly, Massachusetts. This private entity is dedicated to eradicating preventable deaths due to bleeding through the development of innovative medical solutions. Velico's team possesses extensive experience and knowledge in transfusion medicine and medical device development. The company's mission is reinforced through collaborations with trauma surgeons, military medics, first responders, and blood center leaders across various sectors.
About Versiti, Inc.
Versiti, Inc., recognized as a leader in blood health innovation, focuses on enhancing patient health and supporting healthcare partners across the nation. With a commitment to providing value-added solutions in transfusion medicine, transplantation, and blood-related diseases, Versiti strives to meet the diverse needs of its clientele. Their collective efforts aim to improve patient outcomes and optimize healthcare efficiencies nationwide.
Frequently Asked Questions
What is the Blood Center Education Program?
The Blood Center Education Program (BCEP) is a collaborative initiative between Velico and Versiti aimed at providing blood centers with practical experience using advanced plasma technology.
How does Velico's technology improve plasma usage?
Velico's FrontlineODP™ system enhances the plasma's availability by enabling rapid production and longer shelf life, ultimately leading to efficient use during medical emergencies.
Who are the leaders in the collaboration?
Richard Meehan is the President and CEO of Velico, while Dr. Barbara Bryant serves as the Executive Vice President and Chief Medical Officer at Versiti, both emphasizing their shared vision for innovation in blood health.
What funding supports Velico's initiatives?
Velico's development initiatives have received federal funding from the Department of Health and Human Services specifically for strategic preparedness and research development.
What is the current status of the FrontlineODP™ system?
The FrontlineODP™ Dried Plasma System is investigational in nature and currently undergoing clinical trials to establish its safety and efficacy before approval for commercial use.
